Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

IFNL3 mediates interaction between innate immune cells: Implications for hepatitis C virus pathogenesis.

O'Connor KS, Ahlenstiel G, Suppiah V, Schibeci S, Ong A, Leung R, van der Poorten D, Douglas MW, Weltman MD, Stewart GJ, Liddle C, George J, Booth DR.

Innate Immun. 2014 Aug;20(6):598-605. doi: 10.1177/1753425913503385. Epub 2013 Sep 17.

PMID:
24045339
2.

Dendritic cells in hepatitis C virus infection: key players in the IFNL3-genotype response.

O'Connor KS, George J, Booth D, Ahlenstiel G.

World J Gastroenterol. 2014 Dec 21;20(47):17830-8. doi: 10.3748/wjg.v20.i47.17830. Review.

3.

IFNL3/4 genotype is associated with altered immune cell populations in peripheral blood in chronic hepatitis C infection.

O'Connor KS, Read SA, Wang M, Schibeci S, Eslam M, Ong A, Weltman MD, Douglas MW, Mazzola A, Craxì A, Petta S, Stewart GJ, Liddle C, George J, Ahlenstiel G, Booth DR.

Genes Immun. 2016 Sep;17(6):328-34. doi: 10.1038/gene.2016.27. Epub 2016 Jun 16.

4.

Altered effector functions of NK cells in chronic hepatitis C are associated with IFNL3 polymorphism.

Rogalska-Taranta M, Markova AA, Taranta A, Lunemann S, Schlaphoff V, Flisiak R, Manns MP, Cornberg M, Kraft AR, Wedemeyer H.

J Leukoc Biol. 2015 Aug;98(2):283-94. doi: 10.1189/jlb.4A1014-520R. Epub 2015 Jun 1.

5.

IFNL4 and IFNL3 associated polymorphisms strongly influence the spontaneous IFN-alpha receptor-1 expression in HCV-infected patients.

Bordi L, Caglioti C, Garbuglia AR, Lapa D, Castilletti C, Taibi C, Capobianchi MR, Lalle E.

PLoS One. 2015 Feb 12;10(2):e0117397. doi: 10.1371/journal.pone.0117397. eCollection 2015.

6.
7.

IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection.

Eslam M, Leung R, Romero-Gomez M, Mangia A, Irving WL, Sheridan D, Spengler U, Mollison L, Cheng W, Bugianesi E, McLeod D, Zaitoun AM, Attino V, Goeltz D, Nattermann J, Douglas M, Booth DR, George J, Ahlenstiel G.

J Hepatol. 2014 Aug;61(2):235-41. doi: 10.1016/j.jhep.2014.03.039. Epub 2014 Apr 24.

PMID:
24768758
8.

Favourable IFNL3 genotypes are associated with spontaneous clearance and are differentially distributed in Aboriginals in Canadian HIV-hepatitis C co-infected individuals.

Moqueet N, Infante-Rivard C, Platt RW, Young J, Cooper C, Hull M, Walmsley S, Klein MB; Canadian Co-Infection Study Investigators.

Int J Mol Sci. 2015 Mar 20;16(3):6496-512. doi: 10.3390/ijms16036496.

9.

Association of IFNL3 rs12979860 and rs8099917 with biochemical predictors of interferon responsiveness in chronic hepatitis C virus infection.

Fischer J, Böhm S, Müller T, Witt H, Sarrazin C, Susser S, Migaud P, Schott E, Stewart G, Brodzinski A, Fülöp B, van Bömmel F, George J, Berg T.

PLoS One. 2013 Oct 29;8(10):e77530. doi: 10.1371/journal.pone.0077530. eCollection 2013.

10.

Innate and adaptive genetic pathways in HCV infection.

Buchanan R, Hydes T, Khakoo SI.

Tissue Antigens. 2015 Apr;85(4):231-40. doi: 10.1111/tan.12540. Epub 2015 Feb 24. Review.

PMID:
25708172
11.

Efficient virus assembly, but not infectivity, determines the magnitude of hepatitis C virus-induced interferon alpha responses of plasmacytoid dendritic cells.

Grabski E, Wappler I, Pfaender S, Steinmann E, Haid S, Dzionek A, Pietschmann T, Kalinke U.

J Virol. 2015 Mar;89(6):3200-8. doi: 10.1128/JVI.03229-14. Epub 2014 Dec 31.

12.

Hepatic metallothionein expression in chronic hepatitis C virus infection is IFNL3 genotype-dependent.

O'Connor KS, Parnell G, Patrick E, Ahlenstiel G, Suppiah V, van der Poorten D, Read SA, Leung R, Douglas MW, Yang JY, Stewart GJ, Liddle C, George J, Booth DR.

Genes Immun. 2014 Mar;15(2):88-94. doi: 10.1038/gene.2013.66. Epub 2014 Jan 16.

PMID:
24335707
13.

A polymorphism in interferon L3 is an independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis C virus infection.

Chang KC, Tseng PL, Wu YY, Hung HC, Huang CM, Lu SN, Wang JH, Lee CM, Chen CH, Tsai MC, Yen YH, Lin MT, Wu CK, Huang CC, Chen HH, Hu TH.

Clin Gastroenterol Hepatol. 2015 May;13(5):1017-24. doi: 10.1016/j.cgh.2014.10.035. Epub 2014 Nov 13.

PMID:
25460552
14.

CD81/CD9 tetraspanins aid plasmacytoid dendritic cells in recognition of hepatitis C virus-infected cells and induction of interferon-alpha.

Zhang S, Kodys K, Babcock GJ, Szabo G.

Hepatology. 2013 Sep;58(3):940-9. doi: 10.1002/hep.25827. Epub 2013 Jan 18.

15.

Influence of IFNL3.rs12979860 and IFNL4.ss469415590 polymorphism on clearance of hepatitis C virus infection among Egyptians.

Knapp S, Zakaria Z, Hashem M, Zaghla H, Khakoo SI, Waked I, Thursz M, Abdelwahab SF.

Hepatol Int. 2015 Apr;9(2):251-7. doi: 10.1007/s12072-015-9619-z. Epub 2015 Mar 12.

PMID:
25788203
16.

IFN-γ production by human natural killer cells in response to HCV-infected hepatoma cells is dependent on accessory cells.

Zhang S, Saha B, Kodys K, Szabo G.

J Hepatol. 2013 Sep;59(3):442-9. doi: 10.1016/j.jhep.2013.04.022. Epub 2013 May 7.

17.

Deciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patients.

de Castellarnau M, Aparicio E, Parera M, Franco S, Tural C, Clotet B, Martínez MA.

PLoS One. 2012;7(2):e31016. doi: 10.1371/journal.pone.0031016. Epub 2012 Feb 6.

18.

Additive effects of HLA alleles and innate immune genes determine viral outcome in HCV infection.

Fitzmaurice K, Hurst J, Dring M, Rauch A, McLaren PJ, Günthard HF, Gardiner C, Klenerman P; Irish HCV Research Consortium; Swiss HIV Cohort Study.

Gut. 2015 May;64(5):813-9. doi: 10.1136/gutjnl-2013-306287. Epub 2014 Jul 4.

19.

IFNL3 genotype is associated with differential induction of IFNL3 in primary human hepatocytes.

Kurbanov F, Kim Y, Latanich R, Chaudhari P, El-Diwany R, Knabel M, Kandathil AJ, Cameron A, Cox A, Jang YY, Thomas DL, Balagopal A.

Antivir Ther. 2015;20(8):805-14. doi: 10.3851/IMP2974. Epub 2015 Jun 25.

20.

Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.

Aziz H, Raza A, Ali K, Khattak JZ, Irfan J, Gill ML.

Int J Infect Dis. 2015 Jan;30:91-7. doi: 10.1016/j.ijid.2014.09.021. Epub 2014 Nov 20.

Supplemental Content

Support Center